Investor Newsletter

Issue 05 2017

MicroPort

MicroPort® Attends EuroPCR 2017 and Releases Promising Three-month OCT Results from TARGET All Comers Trial

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended EuroPCR 2017 held from May 16 to May 19 in Paris.

On May 17, MicroPort® announced that the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial which demonstrated early vessel healing with Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and showed non-inferiority results compared to Xience family stents. The data were presented during a late-breaking clinical trials session at EuroPCR in Paris. According to the three-month OCT follow-up data, 36 patients have been followed up in three months out of the 50 initially randomized with 18 patients in each arms, for a total of 52 lesions analyzed (24 for Firehawk® and 28 for Xience). The mean neointimal thickness was 75.5μm for Firehawk® and 82.3μm for Xience (P non-inferiority <0.001, with a 90% two-sided confidence interval). This good result is also supported by a percentage of malapposed and uncovered struts of 0.0% (for Firehawk® and Xience arms).

On the same day, MicroPort® released the clinical data of Firehawk® Clinical Trials TARGET All Comer, TARGET I and TARGET II. Meanwhile, two live cases using Firehawk® and a live case using Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®") was broadcasted during this year's EuroPCR.

First Patient Enrolled for Firehawk® Malaysian TARGET MR Clinical Trial

On May 17, MicroPort® announced the enrollment of the first patient for the clinical trial TARGET MALAYSIA REGISTRY ("TARGET MR") jointly launched by MicroPort® and the Ministry of Health of Malaysia. As one part of the TARGET series studies, TARGET MR is another large-scale overseas clinical study for Firehawk® following TARGET All Comer trial in Europe. The first patient was enrolled by Dr. Voon in Pusat Jantung Sarawak Hospital.

TARGET MR is a large-scale, perspective, multi-center, single-arm observational registry trial, jointly launched by MicroPort® and the Ministry of Health of Malaysia. It is planned to enroll a total of 1,153 patients in 10 sites of Malaysia within one year. All of the patients will be implanted in Firehawk®, and the clinical trial's primary endpoint is the target lesion failure ("TLF") rate at 12 months.



MicroPort

ARBORES™ Kyphoplastic Balloon Catheter Receives CE Mark Approval

On May 25, MicroPort® received the CE mark approval for its in-house developed ARBORES™ Kyphoplastic Balloon Catheter ("ARBORES™"), marking the official entry of MicroPort®'s first orthopedic balloon catheter into the European market.

ARBORES™ is intended to be used for the reduction of fractures and/or creation of a void in cancellous bone in the spine, including use during balloon kyphoplasty with accessories like balloon pump, puncture needle, expander and etc. ARBORES™ has two balloon shapes which are Peanut-type and Cylinder-type, and the balloon length ranges from 10mm to 20mm. The overall performance of ARBORES™ is comparable with international leading products. With its CE mark approval of ARBORES™, MicroPort® further diversifies its balloon catheter product line. It is expected that he excellent performance of ARBORES™ will help MicroPort® to expand the European market.

CE



MicroPort® EP
Obtains Thailand FDA Approval for Four Products

On May 10, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained the registration certificate of Thailand FDA for its in-house developed FireMagic™ 3D Irrigated Ablation Catheter, FireMagic™ Cardiac RF Ablation Catheter, EasyFinder™ Fixed Curve Diagnostic Catheter, and EasyLoop™ Circular Mapping Catheter. Previously, the four products received CE certificates and obtained approvals in Brazil, Argentina and etc. The Thailand FDA approval signifies that these products will soon enter the Thailand market and lay a great foundation for MicroPort® EP to further expand the Thailand market.

FireMagic™ 3D Gains CFDA Approval

On May 8, MicroPort® EP obtained a registration certificate from China Food and Drug Administration ("CFDA") for its in-house developed FireMagic™ 3D Ablation Catheter. The device is designed for cardiac electrophysiological mapping. Combined with radio frequency ablation device, FireMagic™ 3D is indicated for use in treating ECG proven arrhythmia with definite clinical symptoms, including AVRT and AVNRT.



MicroPort

MicroPort® Listed as Enterprises Conforming to CSR Standards for Six Consecutive Years

On May 10, the district government of Shanghai Pudong New Area held an awarding ceremony to honor local enterprises that reach the local standards of corporate social responsibility ("CSR") for the year 2015 to 2016. MicroPort® was listed as "enterprises conforming to CSR standards" for the six consecutive years. Since establishment, MicroPort® is enthusiastic about improving the wellbeing of people and communities. The title of "enterprises conforming to CSR standards" fully signifies the recognition of government authority in MicroPort®'s corporate citizenship. In the future, MicroPort® will continue that legacy of charity and generosity benefiting the society and communities with our business philosophy grounded in concepts of contributing towards social harmony.

MicroPort® EP's Project "Cardiac Telemedicine System Based on Smart Device and Cloud" Wins 2016 Shanghai Internet of Things Innovative Product Award

On May 17, MicroPort® EP was granted the 2016 Shanghai Internet of Things Innovative Product Award for its project "Cardiac Telemedicine System Based on Smart Device and Cloud." The project connects hospitals, patients, and physicians by ECG Internet of Things to share data and information regarding ECG collecting, disease diagnosis, professional guiding and post-operation follow-up, to enhance the efficiency of the use of medical resources.



MicroPort® EP's project "Cardiac Telemedicine System Based on Smart Device and Cloud" is the only one related to medical application among the eight projects that obtained Shanghai Internet of Things Innovative Product Award. The project is based on a mobile medical device of MicroPort® EP - ECG Patch. Firstly, the patch is put on the patient's chest to collect ECG, and then the data will be transmitted to a big data platform where it will be automatically analyzed and classified to provide reference for the doctors. If anything wrong is found, the device will recommend doctors according to the type of disease diagnosed and the doctor can use a special App to get connected with the patient and guide him/her to seek medical advice. Once the patient receives operation, the device can record follow-up data accordingly by collecting the patient's ECG regularly. The App also makes follow-up easier as it can directly show the electrocardiography or the electrocardiographic report once receiving the patient's ECG data.

The Article of *"Experience with the Columbus™ 3D EP Navigation System in the Dominican Republic"* Published in Cardiac Rhythm News

Cardiac Rhythm News published the article of "Experience with the Columbus™ 3D EP Navigation System in the Dominican Republic," written by electrophysiologists Manuel Ayala Patete, Dulce Garcia, Mikel Liñero, Vanesa Burgos and Carlos Garcia Lithgow from Centro Cardio-Neuro-Oftalmologico y Transplante ("CECANOT") about their experience using the Columbus™ 3D EP Navigation System ("Columbus™") at their institution. Columbus™ is a product in-house developed byMicroPort® EP. According to statistics, from August 2014 to August 2016, 222 cases of patients between seven and 90 years-old (55% female) were performed using Columbus™. The most frequently treated arrhythmia was ventricular arrhythmia without structural heart disease (35%), followed by atrioventricular nodal re-entrant tachycardia (AVNRT) (22%). Fifteen percent of AF patients underwent pulmonary vein isolation. The immediate success rate was 87.5% for ventricular arrhythmia and 98% for AVNRT. Pulmonary vein isolation in AF was achieved during the procedure in 95% of cases. The complication rate in all procedures was 1.1%, most commonly vascular (72% of all complications). Columbus™ has proved to be reliable for treatment of the simplest to the most complex arrhythmias, in various age groups, with comparable results to other 3D mapping systems.

MicroPort® OrthoRecon Attends CAOS 2017

On May 12, Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort® OrthoRecon") attended the 10th Annual Meeting of Chinese Association of Orthpaedic Surgeons (“CAOS”) and invited several orthopedic experts specialized in minimally invasive technology to discuss the development of minimally invasive technology as well as share their experience in minimally invasive surgeries.

In recent years, the philosophy of “fast return to function” is gaining higher recognition among patients. As the world's first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath™ technique is a milestone in the development of hip replacement. It not only offers patients with small incision, but also provides added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. In the future, MicroPort® OrthoRecon will continue to promote SuperPath™ technique and help drive the development of minimally invasive techniques and spread the philosophy of “fast return to function.”

MicroPort

MicroPort® Endovascular Attends VEC 2017

From May 12 to May 13, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Vascular and Endovascular Conference 2017 (“VEC 2017”) in Beijing for academic exchange. Several experts were invited to deliver speeches introducing the advantages of Castor™ Branched Aortic Stent-Graft System ("Castor™").

Castor™ is the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. Castor™ employs an easy-to-use unibody design, including a main body and a branch stent graft for the left subclavian artery as a whole.

MicroPort® Endovascular Attends Sixth Northwest Vascular Forum

From May 5 to May 6, MicroPort® Endovascular attended the Sixth Northwest Vascular Forum & the 12th Chang'an Vascular Forum held in Xi'an and held a satellite meeting of "the Application of Unibody Stent Design in Endovascular Repair." Professor Qingsheng Lu of Changhai Hospital of the Second Military Medical University shared the design rationale of Castor™". He pointed out, the unibody stent Castor™, jointly developed by MicroPort® Endovascular and Changhai Hospital of the Second Military Medical University, is the first stent system that reconstructs the descending aorta, aortic arch and great vessels of the arch all at once. The device features unique unibody structure – the branch and the main body is unified to avoid endoleak and long-term migration. In addition, it adopts standard design that takes a full consideration of the shape of the arch and the structure of the branch vessel. Also, the design of dual access introducing branch stent graft guarantees precise positioning of the main body and the branch, and the soft inner sheath makes the delivery faster and more precise.

Dongguan Kewei Hosts 2017 EverMend Structural Heart Disease Expert Salon

On May 13, Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei"), a wholly owned subsidiary of MicroPort®, hosted an EverMend Structural Heart Disease Expert Salon in MicroPort® headquarters. Several surgeons from cardiac surgery field were invited to attend the salon and some of them introduced the features of Dongguan Kewei's EverMend Occulder.

The EverMend Occluder series include PDA, ASD, VSD and delivery systems. Compared to competitors in the market, EverMend has advantages in mesh frame, membrane of occluder and delivery systems.

MicroPort

MicroPort® Hosts the Fifth Science and Technology Conference

On May 8, MicroPort® hosted its Fifth Science and Technology Conference in its Shanghai headquarters to share the developments of its on-going R&D projects and awarded R&D talents. 12 project teams from MicroPort® R&D Department, MicroPort® Quality Department, MicroPort® EP, MicroPort® NeuroTech, and MicroPort® CardioFlow MedTech, made presentations about the background, applications, current status and future developments of their projects. The introductions were followed by an active Q&A session which stimulated both the audience and speakers. In this year's Science and Technology Conference, a new session was added to display 50 posters about the brief introduction of research projects, which attracted wide attention and hot discussions from the attendees.

MicroPort® Hosts 2017 Coronary Product Distributor Conference

On May 23, the 2017 Annual Coronary Product Distributor Conference was held in MicroPort® and about 200 people from 110 distributors all over China attended the meeting. During the meeting, Bo Peng delivered a speech in which he pointed out that we should follow the tendency and change accordingly. Afterwards, Dr. Qiyi Luo introduced MicroPort®'s innovative products under development, which attracted great interest from the distributors.

CFDA Official Fanpu Kong Visits MicroPort®

On May 12, Fanpu Kong, Director of Center for Medical Device Evaluation of China Food and Drug Administration ("CFDA") and Lai Xu, Deputy Head of Shanghai Food and Drug Administration visited MicroPort®. MicroPort® Chairman and Chief Executive Officer Dr. Zhaohua Chang and Yimin Xu, Executive Vice President of Regulatory Affairs and Property Management received the team.

In the panel discussion after visiting, the two sides exchanged ideas regarding original equipment manufacturing, cross-provincial manufacturing site, flight check public notification, and detection resources allocation. Director Kong introduced the productive efforts CFDA made in optimizing the approval system and put forward his own opinion regarding the questions raised by enterprise. Director Kong said, this visit not only enhanced the mutual understanding between the CFDA and MicroPort®, but also helped to refine the reform of medical device approval systems and promote the development of China's medical device industry.

MicroPort® Celebrates its 19th Anniversary

On May 15, MicroPort® celebrated its 19th anniversary. Employees watched the flag-raising ceremony in the morning, enjoyed delicious cakes served to them by the management team, and had fun in a dinner party where they were happily singing and dancing to celebrate the company's birthday. With the favorable results MicroPort® has achieved in the past 19 years, we have the confidence and strength to take the company into a bright new era of greater achievements on a global scale. MicroPort® employees will continue to work together to deliver the best and yet affordable therapeutic solutions to save and reshape lives of millions of people around the world.

MicroPort

Investor Newsletter

Issue 05 2017

MicroPort

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com